{
  "guideline": {
    "id": "PA166104962",
    "name": "Annotation of DPWG Guideline for propafenone and CYP2D6",
    "source": "DPWG",
    "version": 32,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104962",
    "relatedChemicals": [
      {
        "id": "PA451131",
        "name": "propafenone",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302705",
      "name": "Recommendation Annotation PA166302705",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104304,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302691",
      "name": "Recommendation Annotation PA166302691",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104290,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This may increase the risk of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302700",
      "name": "Recommendation Annotation PA166302700",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104299,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302695",
      "name": "Recommendation Annotation PA166302695",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104294,
        "html": "<p>The guideline does not provide a recommendation for propafenone in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on propafenone."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302699",
      "name": "Recommendation Annotation PA166302699",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104298,
        "html": "<p>The guideline does not provide a recommendation for propafenone in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on propafenone."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302704",
      "name": "Recommendation Annotation PA166302704",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104303,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302690",
      "name": "Recommendation Annotation PA166302690",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104289,
        "html": "<p>Reduce the dose to 30% of the standard dose, perform an ECG and monitor plasma concentrations.</p>\n"
      },
      "implications": [
        "Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302694",
      "name": "Recommendation Annotation PA166302694",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104293,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This may increase the risk of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302703",
      "name": "Recommendation Annotation PA166302703",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104302,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302698",
      "name": "Recommendation Annotation PA166302698",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104297,
        "html": "<p>The guideline does not provide a recommendation for propafenone in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on propafenone."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302707",
      "name": "Recommendation Annotation PA166302707",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104306,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302693",
      "name": "Recommendation Annotation PA166302693",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104292,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This may increase the risk of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302702",
      "name": "Recommendation Annotation PA166302702",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104301,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302697",
      "name": "Recommendation Annotation PA166302697",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104296,
        "html": "<p>The guideline does not provide a recommendation for propafenone in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on propafenone."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302706",
      "name": "Recommendation Annotation PA166302706",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104305,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302692",
      "name": "Recommendation Annotation PA166302692",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104291,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This may increase the risk of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302701",
      "name": "Recommendation Annotation PA166302701",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104300,
        "html": "<p>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.</p>\n<ul>\n<li>Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.</li>\n<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>\n</ul>\n"
      },
      "implications": [
        "Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302696",
      "name": "Recommendation Annotation PA166302696",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451131",
          "name": "propafenone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104295,
        "html": "<p>The guideline does not provide a recommendation for propafenone in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on propafenone."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
    }
  ],
  "version": "2024-02-29-20-19"
}